EXELIXIS 8-K: Financial Condition, Officer Comp, Exit Activities

TL;DR

**EXELIXIS just filed an 8-K covering financial condition, officer pay, and potential asset sales.**

AI Summary

EXELIXIS, INC. filed an 8-K on January 8, 2024, reporting events that occurred on January 2, 2024. This filing indicates that the company is updating its public record regarding its financial condition, potential exit or disposal activities, and compensatory arrangements for certain officers. For investors, this matters because it signals potential changes in the company's operational structure or executive compensation, which could impact future financial performance and shareholder value.

Why It Matters

This filing updates investors on potential shifts in EXELIXIS's financial health, operational strategy, and executive incentives, all of which can influence the company's stock performance.

Risk Assessment

Risk Level: medium — The mention of 'Cost Associated with Exit or Disposal Activities' introduces uncertainty regarding potential asset sales or restructuring, which can be either beneficial or detrimental depending on the specifics.

Analyst Insight

Investors should monitor subsequent filings for details on the 'Cost Associated with Exit or Disposal Activities' and 'Compensatory Arrangements of Certain Officers' to understand their financial implications for EXELIXIS.

Key Players & Entities

• EXELIXIS, INC. (company) — the registrant filing the 8-K
• January 2, 2024 (date) — date of the earliest event reported
• January 8, 2024 (date) — date the 8-K was filed
• 000-30235 (other) — Commission File Number
• 04-3257395 (other) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $25 m — ncur aggregate charges of approximately $25 million, $13.5 million of which relate to
• $13.5 million — e charges of approximately $25 million, $13.5 million of which relate to the workforce reduct
• $450 million — oard authorized the repurchase of up to $450 million of its common stock before the end of 2
• $450 Million — in the section titled "Announcement of $450 Million Share Repurchase Program for 2024." I

Filing Documents

• exel-20240102.htm (8-K) — 33KB
• exel20240108exhibit991.htm (EX-99.1) — 58KB
• exel-20240102_g1.jpg (GRAPHIC) — 54KB
• exelixis_logoxrgbx2023.jpg (GRAPHIC) — 54KB
• 0000939767-24-000002.txt ( ) — 435KB
• exel-20240102.xsd (EX-101.SCH) — 2KB
• exel-20240102_lab.xml (EX-101.LAB) — 24KB
• exel-20240102_pre.xml (EX-101.PRE) — 12KB
• exel-20240102_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 7, 2024, Exelixis, Inc. (Exelixis or the Company) issued a press release announcing its preliminary unaudited financial results for the fiscal year ended December 29, 2023, providing financial guidance for the fiscal year ending January 3, 2025, and delivered an update on its business. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The preliminary unaudited financial results contained in the press release do not present all information for an understanding of Exelixis' financial condition as of December 29, 2023 and its results of operations for the fiscal year ended December 29, 2023. The audit of Exelixis' financial statements for the fiscal year ended December 29, 2023 is ongoing and could result in changes to the information in the press release. The press release also announced that Exelixis will report its audited financial results for the fiscal year ended December 29, 2023 on February 6, 2024. The information in this report, including the exhibit hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission (SEC) made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

05. Costs Associated with Exit or Disposal Activities

Item 2.05. Costs Associated with Exit or Disposal Activities. On January 5, 2024, the Company's Board of Directors (the Board) authorized a restructuring plan (the Plan) to reduce its workforce and rebalance the Company's cost structure in alignment with its strategic priorities, including reducing real estate commitments and costs and terminating certain licensing partnerships. In connection with the Plan, the Company currently estimates that it will incur aggregate charges of approximately $25 million, $13.5 million of which relate to the workforce reduction. The Company expects these costs will be substantially recognized during the first quarter of 2024. The Plan will result in a workforce reduction of approximately 175 employees or 13% of our total headcount at the end of 2023. The Plan is expected to be implemented and substantially completed during the first quarter of 2024. The foregoing estimates of the charges the Company expects to incur under the Plan are subject to assumptions and actual charges may differ from such estimates. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 5, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Exelixis, the Board increased the size of the Board to 13 members and appointed Mary C. Beckerle, Ph.D. and S. Gail Eckhardt, M.D. to the Board to fill the newly created vacancies, effective immediately. There are no related party transactions between the Company and Drs. Beckerle and Eckhardt that are subject to disclosure under Item 404(a) of Regulation S-K. As non-employee directors, Drs. Beckerle and Eckhardt will be entitled to receive the standard cash and equity compensation for non-employee directors described under the caption "Compensation of Directors" in Exelixis' 2023 proxy statement, filed with the SEC on May 1, 2023, and as set forth on

01. Other Events

Item 8.01. Other Events. Share Repurchase On January 7, 2024, Exelixis announced that the Board authorized the repurchase of up to $450 million of its common stock before the end of 2024. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference only with respect to the discussion in the section titled "Announcement of $450 Million Share Repurchase Program for 2024."

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Press Release d ated January 7, 2024 104 Cover Page Interactive Data File The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. E XELIXIS, I NC. January 8, 2024 /s/ Jeffrey J. Hessekiel Date Jeffrey J. Hessekiel Executive Vice President, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR